512 related articles for article (PubMed ID: 20088947)
21. Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS.
Bergmann-Leitner ES; Legler PM; Savranskaya T; Ockenhouse CF; Angov E
Vaccine; 2011 Aug; 29(35):5940-9. PubMed ID: 21722682
[TBL] [Abstract][Full Text] [Related]
22. Oral immunization with a combination of Plasmodium yoelii merozoite surface proteins 1 and 4/5 enhances protection against lethal malaria challenge.
Wang L; Goschnick MW; Coppel RL
Infect Immun; 2004 Oct; 72(10):6172-5. PubMed ID: 15385527
[TBL] [Abstract][Full Text] [Related]
23. DNA immunization by Plasmodium falciparum liver-stage antigen 3 induces protection against Plasmodium yoelii sporozoite challenge.
Sauzet JP; Perlaza BL; Brahimi K; Daubersies P; Druilhe P
Infect Immun; 2001 Feb; 69(2):1202-6. PubMed ID: 11160023
[TBL] [Abstract][Full Text] [Related]
24. A genetically attenuated parasite vaccine does not require liver stage persistence to elicit sterile protective immunity against sporozoite-induced malaria in mice.
Mikolajczak SA; Vaughan AM; Soliman JM; Kappe SH
J Infect Dis; 2010 Apr; 201(8):1270-1; author reply 1271-2. PubMed ID: 20225958
[No Abstract] [Full Text] [Related]
25. A Plasmodium Parasite with Complete Late Liver Stage Arrest Protects against Preerythrocytic and Erythrocytic Stage Infection in Mice.
Vaughan AM; Sack BK; Dankwa D; Minkah N; Nguyen T; Cardamone H; Kappe SHI
Infect Immun; 2018 May; 86(5):. PubMed ID: 29440367
[TBL] [Abstract][Full Text] [Related]
26. Complete protection against P. berghei malaria upon heterologous prime/boost immunization against circumsporozoite protein employing Salmonella type III secretion system and Bordetella adenylate cyclase toxoid.
Tartz S; Rüssmann H; Kamanova J; Sebo P; Sturm A; Heussler V; Fleischer B; Jacobs T
Vaccine; 2008 Nov; 26(47):5935-43. PubMed ID: 18804138
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity of Plasmodium yoelii merozoite surface protein 4/5 produced in transgenic plants.
Wang L; Webster DE; Campbell AE; Dry IB; Wesselingh SL; Coppel RL
Int J Parasitol; 2008 Jan; 38(1):103-10. PubMed ID: 17681344
[TBL] [Abstract][Full Text] [Related]
28. [Protective immune mechanisms induced by cellular vaccine made of the erythrocytic Plasmodium yoelii].
Yuan J; Xu B; Liu BF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Feb; 26(1):47-51. PubMed ID: 15052774
[TBL] [Abstract][Full Text] [Related]
29. Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine.
Wang R; Charoenvit Y; Corradin G; Porrozzi R; Hunter RL; Glenn G; Alving CR; Church P; Hoffman SL
J Immunol; 1995 Mar; 154(6):2784-93. PubMed ID: 7876549
[TBL] [Abstract][Full Text] [Related]
30. Comparative efficacy of pre-erythrocytic whole organism vaccine strategies against the malaria parasite.
Friesen J; Matuschewski K
Vaccine; 2011 Sep; 29(40):7002-8. PubMed ID: 21787828
[TBL] [Abstract][Full Text] [Related]
31. Genetically modified Plasmodium highlights the potential of whole parasite vaccine strategies.
Good MF
Trends Immunol; 2005 Jun; 26(6):295-7. PubMed ID: 15922944
[TBL] [Abstract][Full Text] [Related]
32. IL-12p40-independent induction of protective immunity upon multiple Plasmodium berghei irradiated sporozoite immunizations.
Romero JF; Ibrahim GH; Renggli J; Himmelrich H; Graber P; Corradin G
Parasite Immunol; 2007 Nov; 29(11):541-8. PubMed ID: 17944743
[TBL] [Abstract][Full Text] [Related]
33. Liver or blood-stage arrest during malaria sporozoite immunization: the later the better?
Nganou-Makamdop K; Sauerwein RW
Trends Parasitol; 2013 Jun; 29(6):304-10. PubMed ID: 23608185
[TBL] [Abstract][Full Text] [Related]
34. The Effects of radiation on the safety and protective efficacy of an attenuated Plasmodium yoelii sporozoite malaria vaccine.
Chattopadhyay R; Conteh S; Li M; James ER; Epstein JE; Hoffman SL
Vaccine; 2009 Jun; 27(27):3675-80. PubMed ID: 19071177
[TBL] [Abstract][Full Text] [Related]
35. Active immunisation with RAMA does not provide protective immunity against Plasmodium yoelii challenge despite its association with protective responses in endemic populations.
Kats LM; Wang L; Murhandarwati EE; Mitri K; Black CG; Coppel RL
Vaccine; 2008 Jun; 26(26):3261-7. PubMed ID: 18468741
[TBL] [Abstract][Full Text] [Related]
36. Dendritic cells induce immunity and long-lasting protection against blood-stage malaria despite an in vitro parasite-induced maturation defect.
Pouniotis DS; Proudfoot O; Bogdanoska V; Apostolopoulos V; Fifis T; Plebanski M
Infect Immun; 2004 Sep; 72(9):5331-9. PubMed ID: 15322030
[TBL] [Abstract][Full Text] [Related]
37. Rhop-3 protein conservation among Plasmodium species and induced protection against lethal P. yoelii and P. berghei challenge.
Wang T; Fujioka H; Drazba JA; Sam-Yellowe TY
Parasitol Res; 2006 Aug; 99(3):238-52. PubMed ID: 16541261
[TBL] [Abstract][Full Text] [Related]
38. Plasmodium: mammalian codon optimization of malaria plasmid DNA vaccines enhances antibody responses but not T cell responses nor protective immunity.
Dobaño C; Sedegah M; Rogers WO; Kumar S; Zheng H; Hoffman SL; Doolan DL
Exp Parasitol; 2009 Jun; 122(2):112-23. PubMed ID: 19249301
[TBL] [Abstract][Full Text] [Related]
39. Prophylactic potential of liposomized integral membrane protein of Plasmodium yoelii nigeriensis against blood stage infection in BALB/c mice.
Sharma SK; Gupta C; Dwivedi V; Misra-Bhattacharya S; Mohammad O
Vaccine; 2007 Mar; 25(11):2103-11. PubMed ID: 17241709
[TBL] [Abstract][Full Text] [Related]
40. A single dose of genetically-attenuated malaria blood-stage parasites protects against two Plasmodium species infections.
Deveci G; Kamil M; Aly ASI
Vaccine; 2023 Feb; 41(7):1281-1285. PubMed ID: 36653222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
